OBJETIVO: Apresentar os resultados da experiência clínica inicial de 100 casos de mulheres portadoras de miomatose sintomática que foram submetidas a embolização das artérias uterinas como forma de tratamento principal. Apresenta-se, também, extensa revisão bibliográfica sobre o tema, para determinar as indicações e contra-indicações, bem como as eventuais complicações do método. MATERIAL E MÉTODO: Cem pacientes com miomatose sintomática foram submetidas a embolização das artérias uterinas como única forma de tratamento. O principal sintoma que indicou a intervenção foi o aumento do fluxo menstrual em 79 pacientes e dor associada à miomatose em 21. O diagnóstico de miomatose foi realizado por meio de ultra-sonografia em 75 pacientes, e pela associação de ultra-sonografia e ressonância magnética em 25 pacientes. O volume uterino médio avaliado por esses métodos de imagem resultou em 487 cm³. Os procedimentos foram realizados em duas instituições hospitalares: uma pública, onde foram atendidas 56 pacientes dependentes do Sistema Único da Saúde (SUS), e outra particular, onde foram atendidas 46 pacientes com plano de assistência médica. Setenta e seis pacientes foram avaliadas clinicamente após 12 semanas da realização da embolização uterina. RESULTADOS: O procedimento foi completado com sucesso em 97% dos casos, utilizando-se técnica convencional. O acompanhamento e a avaliação clínica após 12 semanas evidenciou que houve melhora dos sintomas em mais de 90% das pacientes. Verificou-se, ainda, redução de volume uterino de 52%. Não foram observadas complicações técnicas ou clínicas relevantes. CONCLU-SÃO: A técnica de embolização uterina para tratamento da miomatose sintomática é um método simples, eficiente e seguro. Unitermos: Miomas; Embolização uterina; Tumor ginecológico; Menorragia.Uterine embolization for the treatment of symptomatic fibroids. Initial results and review of the literature. PURPOSE: To report the initial clinical experience after the treatment of 100 women suffering of symptomatic fibroids who were submitted to uterine artery embolization as the main form of treatment. We also present an extensive review of literature on the subject in order to determine the indications and contraindications, and the possible complications of this method. MATERIAL AND METHOD: One hundred patients with symptomatic fibroids were submitted to uterine artery embolization as the main form of treatment. The main symptoms that justified the intervention were increased menstrual flow in 79 patients and pain related to the fibroids in 21 patients. Diagnosis was made using ultrasound alone in 75 patients and ultrasound and magnetic resonance imaging in 25 patients. The mean uterine volume measured using these imaging methods was 487cm³. The procedure was performed in two Institutions: 56 procedures in a public Institution in patients attended by the public health system, and 46 patients with health insurance treated in a private clinic. Seventy-six patients were followed clinically during 12 weeks after uterine embolizat...
Objective: To evaluate the safety and efficacy of using highly compressible calibrated microspheres in uterine artery embolization (UAE) for the treatment of uterine fibroids. Materials and Methods: This was a prospective multicenter study. Thirty-two women with symptomatic uterine fibroids were selected for UAE between January 2019 and March 2020. The participants completed the Uterine Fibroid Symptom and Quality of Life (UFS-QOL) questionnaire, underwent contrast-enhanced pelvic magnetic resonance imaging (MRI), and were submitted to anti-Müllerian hormone measurement, subsequently undergoing UAE with Embosoft microspheres. After six months, the patients again completed the UFS-QOL questionnaire and underwent pelvic MRI. Results: The most common symptoms were abnormal uterine bleeding (in 81.3% of the cases), pelvic pain (in 81.3%), and compression (in 46.9%). Of the 32 patients evaluated, 12 (37.5%) had anemia due to abnormal uterine bleeding. Thirty patients completed the study. Among those patients, we observed median reductions of 21.4% in uterine volume and 15.9% in dominant fibroid volume. We identified no adverse events that could be attributed to the material itself, although there were events attributed to the UAE procedure in general. Conclusion: For the treatment of uterine fibroids, UAE using Embosoft microspheres shows satisfactory results, providing reductions in uterine and dominant fibroid volumes, with a low rate of adverse events, and improving patient quality of life, as well as demonstrating safety and efficacy.
IntroduçãoA menopausa e o período subseqüente são marcados por mudanças significativas no padrão hormonal no organismo feminino. Essas alterações são bem nítidas quanto ao eixo hipotálamo-hipófise-ovário e também quanto à atividade da glândula supra-renal.
pela colaboração inestimável na dedicação ao atendimento às mulheres deste trabalho e realização dos exames de ultra-sonografia.
The rates of placenta praevia and accreta are rising, probably as a result of increasing rates of cesarean delivery, as well as maternal age and assisted reproductive technologyIn this paper, we present a case report of a pregnancy complicated by anterior placenta praevia and accreta, in which the uterine extra-abdominal exposure technique was used to proceed the hysterotomy in the uterine fundus in order to avoid excessive bleeding and also to better evaluate the lower segment and consequent hysterectomy requirement. The main objective of this procedure is to describe a surgical technique which should guide the hysterotomy, in a position far enough away from the placenta site (fundus or posterior), in order to prevent bleeding complications in placental accreta disorders.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.